New Haven, Conn. — The eyes have been called the window to the brain. It turns out they also serve as an immunological barrier that protects the organ from pathogens and even tumors, Yale researchers have found. In a new study, researchers showed that vaccines injected into the eyes of...
Latest News
WASHINGTON, DC – Vosoritide’s first global phase 2 study showed an average increased growth rate of 1.8 cm per year in children with hypochondroplasia, a genetic cause of short stature in children, according to researchers from Children’s National Hospital. “This is the first medicine that has been developed to specifically...
An international team of scientists studying a rare genetic disease discovered that a bundle of proteins with the long-established function of keeping chromosomes together also plays an important role in regulating genes in humans. When gene regulation is disrupted in the multisystem genetic disease Cornelia deLange syndrome (CdLS), children may...
EL PASO, Texas – Could the solution to the decades-long battle against malaria be as simple as soap? In a new study published in PLOS Neglected Tropical Diseases, scientists at The University of Texas at El Paso have made a compelling case for it. The team has found that adding small quantities...
NEW YORK, NY — IN8bio, Inc. (NASDAQ: INAB), a leading clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced a publication in Frontiers in Immunology that reviews IN8bio’s novel approach for solid tumors, such as glioblastoma (GBM), an aggressive form of brain cancer. Cellular therapies, particularly chimeric antigen...
Nashville, Tennessee – A new study in the peer-reviewed Journal of Child and Adolescent Psychopharmacology estimated the incidence of neuroleptic malignant syndrome (NMS), a potentially fatal adverse effect of antipsychotic treatment, among individuals ages 5-24 years. Click here to read the article now. Wayne Ray, PhD, from the Vanderbilt University School of...
Huntington’s disease affects the brain and is always inherited. The only treatments for HD manage symptoms, some of them prescribed off-label, borrowed from other conditions. A treatment that addresses the underlying cause of the disease, which delays onset or slows progression, has been elusive for decades. A disease like no other...
PLANEGG, Germany & MUNICH & WILMINGTON, Del. – Incyte (NASDAQ:INCY) and MorphoSys AG (FSE:MOR; NASDAQ:MOR) today announced that the first patient has been dosed in the pivotal Phase 3 frontMIND study evaluating tafasitamab and lenalidomide in addition to rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) compared to R-CHOP alone as first-line treatment...
WILMINGTON, Del. & PLANEGG, Germany & MUNICH – Incyte (Nasdaq:INCY) and MorphoSys AG (FSE:MOR; NASDAQ:MOR) today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending the conditional marketing authorization of tafasitamab in combination with lenalidomide, followed by tafasitamab monotherapy,...
WILMINGTON, Del. & BOSTON–(BUSINESS WIRE)– Incyte (NASDAQ:INCY) and MorphoSys US Inc., a fully owned subsidiary of MorphoSys AG (FSE: MOR; NASDAQ:MOR), today announced new three-year follow-up data from the ongoing Phase 2 L-MIND study of tafasitamab (Monjuvi®) in combination with lenalidomide in adult patients with relapsed or refractory diffuse large...